Longer follow-up from two studies supports neoadjuvant over adjuvant immune checkpoint inhibition in patients with resectable melanoma and clinically or radiologically detectable metastasis, plus useful insights gained from biomarker analyses will help refine treatment strategies

Despite the presentation of encouraging study findings with novel immunotherapy-based therapies, long-term outcomes are needed to better understand the magnitude of clinical benefit and many questions remain around off-target toxicity and the identification of patients most likely to respond to treatment

Potentially practice-changing data were presented for atezolizumab plus bevacizumab, and camrelizumab plus rivoceranib in hepatocellular carcinoma

While telisotuzumab adizutecan demonstrated early antitumour activity, only modest benefits were seen with VCN-01 added to standard care

The combination, incorporating the novel antibody–drug conjugate, may transform first-line treatment in the setting, but crucial issues need to be addressed

Presidential Symposium presentation provides insights into the role of 177Lu-PSMA-617 in the treatment of hormone-sensitive prostate cancer, with results also presented in castration-resistant disease 

Phase III data show significant survival improvements with the TROP2-directed antibody–drug conjugate after progression on EGFR tyrosine kinase inhibitors

Effective biomarkers and histology-focused enrichment trials are now needed to further improve patient outcomes

Robust efficacy findings and unexpectedly low haemorrhagic events were observed with the bispecific antibody but results will only change practice if benefits translate into overall survival and are replicated beyond China

Rivoceranib after prior therapy and peri-operative pembrolizumab demonstrates promising efficacy but it is not superior to the current standard therapy